Abstract: PET absolute quantitative myocardial blood flow (MBF) imaging has significant clinical incremental value in the diagnosis, risk stratification, and prognosis evaluation of coronary artery disease. Still, it has not been widely used in the clinic due to the limitation of conventional positron myocardial perfusion imaging agents. The successful development of 2-tert-butylchloro-54-(2-fluoro-¹⁸F-ethoxymethyl) phenyl methoxy-3(2H)-pyridazine ketone (¹⁸F-Flurpiridaz) has pioneered a new field of positron myocardial perfusion imaging agents. It has excellent absolute quantitative property in MBF and myocardial flow reserve and has obvious advantages over traditional positron myocardial perfusion imaging agents in physical properties, myocardial extraction rate, and application convenience in the clinic, also, it has entered clinical phase Ⅲ research process and has become the most promising ¹⁸F-labeled PET myocardial perfusion imaging agents. The authors review the research progress in ¹⁸F-Flurpiridaz PET absolute quantitative MBF imaging.